A physician who respects your product can carry more weight with other doctors than a rep. That is why almost every regen product company wants a KOL program. It is also why so many build one without a single written rule. This post lays out eight steps that let you work with key opinion leaders and stay on the right side of the FTC and CMS.
TLDR: A KOL program is an endorsement program, and the FTC treats it as one. Decide whether each KOL is educating or promoting, and keep the two apart. Disclose the paid connection everywhere the KOL talks about the product. Pay for time and expertise, never for orders. Hold the KOL to the same claim ceiling as your reps. Know whether Open Payments reporting applies to your product. Read on for the eight steps, the mistakes we see most, and a scenario that shows how a good program goes wrong.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.
Doctors trust other doctors. So what turns a doctor’s interest into an order? Training, use cases, open talk, and research that compares one method with another. A respected peer who has used the product delivers all four in one conversation.
That is the whole reason a KOL program works. It is also the reason it needs rules. The moment you pay that peer, the FTC sees an endorser with a paid connection. CMS may see a payment it expects you to report.
I have worked with dozens of manufacturers and distributors on consulting and marketing. Here are the eight steps, in the order I would build the program.
Why a KOL Program Works and Why It Needs Rules
A KOL program borrows a doctor’s good name and lends it to your product. Doctors trust other doctors.
The FTC has a name for this. When a company pays someone to speak well of its product, that person is an endorser. The paid connection must be disclosed, and the rules sit in 16 CFR Part 255, the FTC’s Endorsement Guides.
Then there is the money trail. If your product falls under the CMS Open Payments program, your KOL fees become public data.
Most companies I meet sign their first KOL before they know any of this. The rest gets fixed after a problem, and that costs more. So let us set the rules first.
The Two Rules Under Every KOL Program
Every safe KOL program rests on two federal rules: the FTC Endorsement Guides and the CMS Open Payments program. The first governs what your KOL says. The second governs how your payments to the KOL get reported.
Start with the FTC. Section 255.5 of the Endorsement Guides covers material connections. A connection must be disclosed when it might change how the audience weighs the endorsement, and the audience would not expect it. Payment counts. Free product counts. A consulting contract counts.
The FTC’s own Endorsement Guides Q&A goes further. Expert spokespersons should disclose their connections when they promote a product outside traditional advertising. That includes talks, podcasts, and social posts.
Section 255.3 covers the expert side. An expert’s endorsement must be supported by an actual exercise of the expertise the expert is presented as having. A physician who never used the product cannot be presented as a physician who evaluated it.
Now CMS. The Open Payments program collects payments and transfers of value that reporting companies make to physicians and other covered recipients. Those companies make covered drugs, devices, biologicals and medical supplies. Ask counsel if that is you. That is a question for counsel, and it needs an answer before the first check clears.
With those two rules in view, the eight steps are easy to follow.
Steps 1 to 4: Define the Role, Disclose, Pay for Time, Set the Ceiling
The first four steps decide what the KOL is, what the audience is told, what the money is for, and what may be said.
Step 1: define the role, education or promotion, and keep them apart. A KOL who teaches a technique at a course is doing education. A KOL who presents your product for the company is doing promotion. Both are allowed inside the product’s claim ceiling. A comparison claim needs head-to-head evidence, and most regen products do not have it. Mixing them in one talk is where trouble starts. The audience hears a lecture and gets an ad. Write the role into the agreement and into the talk’s title.
Step 2: disclose the material connection everywhere the KOL speaks about the product. Not in the contract, on the stage. The FTC Q&A says a disclosure needed in one post is probably needed in all of them. The same page says a disclosure buried in a video description or behind a link is not enough. Put it on the first slide, in the first minute, and in the first line of the caption.
Step 3: pay for time and expertise, never for outcomes or volume. A fee for a lecture, a case review, or a protocol draft is a fee for work. A fee that rises with the KOL’s orders is something else. Set an hourly or per-event rate that matches the work and leave it there.
Step 4: give the KOL the same claim ceiling as the rep. Your product’s status sets what anyone may say about it. A physician’s license does not raise that ceiling. A 361 HCT/P cannot be described as treating a condition, no matter who holds the microphone. Hand the KOL the same one-page claim sheet your reps carry. The same goes for the deck. For a cell product, it carries no mechanism language, no cell counts per vial, and no supplier white paper.
Those four steps set the frame; the next four keep it standing over time.
Steps 5 to 8: Review the Deck, Track Payments, Label Testimonials, Document
The last four steps are about control after the agreement is signed. A KOL program drifts the way clinic marketing drifts, one slide and one sentence at a time.
Step 5: review the deck before the talk. When a product company hands us a deck to review, the first things we flag are non-compliant claims, wording too complex for the buyer, and weak graphics. Build a review step into every event, with enough lead time to fix the slides.
Step 6: know whether Open Payments applies to your product, and track every transfer of value from day one. If it applies, you will report fees, travel, meals, and anything else of value the KOL received. The CMS program gives covered recipients a window to review and dispute records before publication. Keep the ledger clean so nothing surprises the KOL.
Step 7: never let a testimonial pass as a clinical opinion. “I used this in my practice and here is what I saw” is a testimonial from a paid endorser, so it needs the disclosure and real use. It also has to stay inside the claim ceiling, because what the KOL saw in patients is an outcome claim. The FTC’s reviews and testimonials rule applies the same logic to AI-generated reviews and testimonials. “The published evidence for this class of product shows the following” is an expert opinion that must rest on real work with that evidence. Label each one, and never let the first borrow the weight of the second.
Step 8: document the agreement. Write down the role, the fee basis, the claim ceiling, the disclosure language, the deck review step, and who owns the recording. The FTC Guides hold the advertiser responsible for guiding endorsers, monitoring them, and correcting problems. A written agreement is the first piece of evidence that you did all three.
Eight steps in, most KOL programs are better protected; the ones that fail tend to trip on the same few mistakes.
Common KOL Program Mistakes
The mistakes cluster in four places: undisclosed connections, claims that outrun the product, pay tied to sales, and testimonials dressed up as data.
Undisclosed connections lead the list. The KOL posts about the product on LinkedIn and forgets the tag. The moderator introduces the KOL as an independent expert. The company reposts the talk without the disclosure that was on the stage. Each one is a separate gap, and the FTC Q&A is clear that the company is responsible for what others do on its behalf. If your KOLs post, what we know about how LinkedIn ranks physician posts still applies, with the disclosure rule on top.
Claims that outrun the product come second. Reps routinely make statements to clinic owners that are not FDA compliant, and we have watched that language travel from the pitch into the clinic’s own ads. A KOL saying the same thing on a recorded webinar travels farther and lasts longer. The claim sheet in Step 4 exists to stop this.
Sales-linked pay is the third mistake, and it usually hides inside a “consulting” contract. A bonus for hitting a regional number is not consulting. If a KOL agreement has any line that moves with orders, send it to counsel before anyone signs.
Testimonials dressed up as data close the list. A slide that reads “in my hands, most patients did well” is a personal report from a paid endorser. When we ask a company what the evidence behind a sentence like that is, what comes back is usually vendor materials and often not much at all. Keep the personal report labeled as personal, and keep it inside the claim ceiling.
A scenario shows how all four can show up in one program that started with good intentions.
A Scenario: One Program, Four Fixes
Picture a product company in the orthobiologics space that signs its first KOL. The KOL is a sports medicine physician who has used the product for a year and likes it. The company pays a flat fee per webinar, which is right. Then the plan drifts in four places at once.
The webinar invitation calls the physician an independent expert. The slides, written by the physician, include a line about the product resolving a condition. The sales director offers a year-end bonus if the physician’s region grows. And the company posts the recording to its channel with no disclosure.
Now apply the eight steps. The invitation is rewritten to say the physician is a paid consultant to the company. The disclosure goes on the first slide and in the first minute of the recording. The bonus offer is withdrawn and replaced with a higher flat fee for the added work. The condition claim comes out of the deck, because the product’s status does not allow it from anyone.
The company also asks counsel whether Open Payments applies to its product. Counsel says it does. The fees and travel from the first event go into the ledger, and the physician is told what will be reported. The webinar runs a month late. The virtual seminar funnel that follows keeps every rule the first event learned the hard way.
None of that cost the company the KOL. It cost a month, a fair trade against a public correction.
Frequently Asked Questions
What Is a KOL Program in Regenerative Medicine?
A KOL program is a relationship between a product company and a respected physician or scientist who speaks about the product to peers. The company pays in fees, travel, or product. That makes the KOL an endorser with a material connection in the FTC’s eyes, and the same disclosure and claim rules apply.
Does a KOL Have to Disclose Being Paid?
Yes, when the connection might change how the audience weighs what the KOL says and the audience would not expect it. That is the standard in 16 CFR 255.5. A paid physician speaking about a product to other physicians meets it. The disclosure must be clear and placed where the audience will see it: on the slide and in the recording, not only in a footnote.
Does Open Payments Apply to a 361 Product Company?
It depends on the product and how it is covered, and counsel decides the answer. The CMS Open Payments program covers makers of covered drugs, devices, biologicals and medical supplies, and counsel confirms whether that includes you. Ask early, because the ledger has to start with the first payment.
Can We Pay a KOL a Bonus Tied to Sales?
Treat that as a question for counsel, and expect the answer to be a hard no. A fee tied to orders changes what the KOL is likely to say and turns an expert opinion into a sales incentive. Pay for time and expertise at a rate that matches the work. If federal health programs pay for the product, the federal Anti-Kickback Statute can apply to what you pay doctors. Counsel decides.
How Does a KOL Program Fit a Physician Acquisition Funnel?
A KOL sits in the middle of the funnel, where a curious physician needs training, use cases, and peer discussion before a first order. That is what a well-run KOL talk provides. The physician funnel stages show where the KOL event belongs and what should come before and after it. If a KOL wants to share a patient story, the rules for asking for reviews the right way cover the disclosure side.
Key Takeaways
- A KOL program is an endorsement program, and the FTC Endorsement Guides apply to every talk, post, and recording.
- Disclose the paid connection on the slide, in the recording, and in the caption, not only in a contract.
- Pay for time and expertise at a flat rate, and send any sales-linked payment term to counsel before signing.
- The product’s status sets the claim ceiling for the KOL exactly as it does for the rep.
- Review every deck before the talk, because non-compliant claims are the first thing we flag in product company materials.
- Ask counsel whether Open Payments applies to your product, and track every transfer of value from the first payment.
Your Next Step
A KOL program built on these eight steps is one of the strongest tools a regen product company has, because it delivers what physicians say moves them. The rules are there so the program survives its own success, when the recording is public and the payments are searchable.
If you already have KOL agreements, decks, or recordings, Regen Portal can review them against the FTC rules and the claim ceiling for your product. If you are building from scratch, our marketing compliance services work starts with the claim sheet and the disclosure language, then builds the events around them.
PS: Send us one KOL deck or recording and we will give you a free compliance review of the claims and disclosures in it.
Email: hello@regenportal.com
YouTube: Subscribe to the channel
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
